Anis A Khan

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 3

Top Topics

Liver Metastases

Chemotherapy Induced

Top Venues

Cancer immunology, immunotherapy : CII

CPT: pharmacometrics & systems pharmacology

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Hongtao Yu, Sebastian Ueckert, Lina Zhou, Jenny Cheng, Darren Robertson, Lars Hansen, Armando Flor, Victoria Parker, Bengt Hamrén, Anis A Khan
Exposure-response modeling for nausea incidence for cotadutide using a Markov modeling approach. CPT: pharmacometrics & systems pharmacology (2024)
Johanna Bendell, Patricia LoRusso, Michael James Overman, Anne M Noonan, Dong Wan Kim, John H Strickler, Sang-We Kim, Stephen Clarke, Thomas J George, Peter S Grimison, Minal Barve, Manik Amin, Jayesh Desai, Trisha Michel Wise-Draper, Steven Eck, Yu Jiang, Anis A Khan, Yuling Wu, Philip Martin, Zachary A Cooper, Nairouz Elgeioushi, Nancy Mueller, Rakesh Kumar, Sandip Pravin Patel
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer immunology, immunotherapy : CII (2023)
Xuyang Song, Robin Kate Kelley, Anis A Khan, Nathan Standifer, Diansong Zhou, KyoungSoo Lim, Rajesh Krishna, Lucy Liu, Kun Wang, Patricia McCoon, Alejandra Negro, Philip He, Megan Gibbs, John F Kurland, Ghassan K Abou-Alfa
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)